The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

AIMS: The number of pulmonary arterial hypertension (PAH) patients with comorbidities is increasing and there are limited data on response to PAH‐targeted therapies in this population. These post hoc analyses explored the effect of selexipag in PAH patients with cardiovascular comorbidities in the G...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenkranz, Stephan, Channick, Richard, Chin, Kelly M., Jenner, Bartosz, Gaine, Sean, Galiè, Nazzareno, Ghofrani, Hossein‐Ardeschir, Hoeper, Marius M., McLaughlin, Vallerie V., Du Roure, Camille, Rubin, Lewis J., Sitbon, Olivier, Tapson, Victor, Lang, Irene M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2021
Materias:
Comorbidities
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298818/
https://www.ncbi.nlm.nih.gov/pubmed/34806261
http://dx.doi.org/10.1002/ejhf.2369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298818/
https://www.ncbi.nlm.nih.gov/pubmed/34806261
http://dx.doi.org/10.1002/ejhf.2369

Ejemplares similares